# Altasciences

> Altasciences is a privately held North American contract research and drug manufacturing organization that helps biotechnology and pharmaceutical companies move experimental medicines from lead-candidate selection through preclinical safety work, formulation, early clinical trials, bioanalysis, and proof of concept. Its pitch is organizational as much as scientific: put services that sponsors often buy from separate vendors under one operating structure, assign a single program manager, and make earlier go-or-no-go decisions with fewer handoffs.

- **Founded:** 1992
- **Headquarters:** Laval, Canada
- **Team size:** 2,200+ employees across nine North American cities, according to the company careers page
- **Products:** Preclinical Services, Clinical Services, Bioanalysis, Manufacturing and Analytical Services, Research Support Services
- **Notable:** Shifted from a generic-drug testing CRO into an integrated early-phase CRO/CDMO., Expanded to nine North American cities and more than 2,200 employees, according to company career materials., Completed its first U.S. FDA inspection in 2001.

## Products & services

- **Preclinical Services** — GLP and non-GLP safety assessment, toxicology and in vivo studies for small and large molecules across multiple species.
- **Clinical Services** — Clinical pharmacology studies from first-in-human through Phase II, including proof of concept, bioavailability, bioequivalence, DDI and special-population studies.
- **Bioanalysis** — Small- and large-molecule bioanalysis, biomarkers, immunogenicity, LC-MS and ligand-binding work from preclinical programs through Phase IV.
- **Manufacturing and Analytical Services** — Formulation, method development, clinical supply, ICH stability work and small-molecule manufacturing from Phase I into commercial scale.
- **Research Support Services** — Program and project management, regulatory strategy, medical writing, biostatistics, data management, monitoring and quality consulting.
- **Altasciences Acceleration Platform** — A coordinated development model using centralized scheduling, shared data and a single cross-functional program manager to reduce gaps between workstreams.

## Achievements

- Shifted from a generic-drug testing CRO into an integrated early-phase CRO/CDMO.
- Expanded to nine North American cities and more than 2,200 employees, according to company career materials.
- Completed its first U.S. FDA inspection in 2001.
- Won a 2024 CRO Leadership Award for Capabilities among small-pharma respondents.
- Won a 2025 CDMO Leadership Award for Small Molecule Dosage Form in North America.
- Received an EcoVadis Gold Medal in 2025 for ESG efforts.
- Former CEO Chris Perkin was named to PharmaVoice's 100 most inspiring leaders multiple times and became a Lifetime Red Jacket honoree.

## Latest updates

- **2026-07** — Altasciences and Evidence Matters announced a nonclinical automation proof of concept using RegulatoryFlow.
- **2026-06** — The company reported support for a development milestone for Steel Therapeutics' Fizurex.
- **2026-05** — Altasciences announced a strategic partnership with Certara for model-informed early drug development.
- **2026-02** — Marie-Hélène Raigneau became CEO and Chris Perkin moved to Executive Chairman.
- **2025-08** — Altasciences announced collaborations with Evidence Matters and Steel Therapeutics and received an EcoVadis Gold Medal.
- **2025-07** — The company announced a preclinical collaboration with VoxCell BioInnovation.

## Links

- Website: https://www.altasciences.com/
- LinkedIn: https://www.linkedin.com/company/altasciences
- Twitter/X: https://twitter.com/altasciences
- YouTube: https://www.youtube.com/@Altasciences
- Facebook: https://facebook.com/Altasciences/

---

Profile page: https://yespress.io/altasciences
Published by YesPress — https://yespress.io
Last updated: 2026-08-23